Trial Outcomes & Findings for Imaging Study of Glioblastomas Treated With Avastin (NCT NCT01549392)

Last Updated: 2014-09-15

Results Overview

participants who had reduction of tumor size from avastin at 3 months

Recruitment status

TERMINATED

Study phase

Target enrollment

3 participants

Primary outcome timeframe

at 3 months after initial DECT and MR spectroscopy

Results posted on

2014-09-15

Participant milestones
Measure	DECT/MRS in Patients Receiving Avastin 3 Glioma Patients underwent DECT and MRS pre-Avastin and 3 months later after receiving avastin 10 mg/kg iv q2weeks DECT: DECT at tumor progression and 3 months later MR spectroscopy: MR spectroscopy at tumor progression and 3 months later Avastin 10 mg/kg iv q2weeks	DECT/MRS in Glioma Patients Not Receiving Avastin 0 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1 DECT: DECT at tumor progression and 3 months later MR spectroscopy: MR spectroscopy at tumor progression and 3 months later
Overall Study STARTED	3	0
Overall Study COMPLETED	2	0
Overall Study NOT COMPLETED	1	0

Reasons for withdrawal
Measure	DECT/MRS in Patients Receiving Avastin 3 Glioma Patients underwent DECT and MRS pre-Avastin and 3 months later after receiving avastin 10 mg/kg iv q2weeks DECT: DECT at tumor progression and 3 months later MR spectroscopy: MR spectroscopy at tumor progression and 3 months later Avastin 10 mg/kg iv q2weeks	DECT/MRS in Glioma Patients Not Receiving Avastin 0 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1 DECT: DECT at tumor progression and 3 months later MR spectroscopy: MR spectroscopy at tumor progression and 3 months later
Overall Study Withdrawal by Subject	1	0

Imaging Study of Glioblastomas Treated With Avastin

Baseline characteristics by cohort
Measure	DECT/MRS in Patients Receiving Avastin n=3 Participants -15 Glioma Patients with progression will undergo DECT and MRS pre-Avastin and 3 months later DECT: DECT at tumor progression and 3 months later MR spectroscopy: MR spectroscopy at tumor progression and 3 months later	DECT/MRS in Glioma Patients Not Receiving Avastin 15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1 DECT: DECT at tumor progression and 3 months later MR spectroscopy: MR spectroscopy at tumor progression and 3 months later	Total n=3 Participants Total of all reporting groups
Age, Continuous	50 years n=5 Participants	—	50 years n=5 Participants
Age, Categorical <=18 years	0 participants n=5 Participants	—	0 participants n=5 Participants
Age, Categorical Between 18 and 65 years	3 participants n=5 Participants	—	3 participants n=5 Participants
Age, Categorical >=65 years	0 participants n=5 Participants	—	0 participants n=5 Participants
Gender Female	2 participants n=5 Participants	—	2 participants n=5 Participants
Gender Male	1 participants n=5 Participants	—	1 participants n=5 Participants
Region of Enrollment Canada	3 participants n=5 Participants	—	3 participants n=5 Participants

Timeframe: at 3 months after initial DECT and MR spectroscopy

participants who had reduction of tumor size from avastin at 3 months

Outcome measures
Measure	DECT/MRS in Patients Receiving Avastin n=3 Participants -15 Glioma Patients with progression will undergo DECT and MRS pre-Avastin and 3 months later DECT: DECT at tumor progression and 3 months later MR spectroscopy: MR spectroscopy at tumor progression and 3 months later	DECT/MRS in Glioma Patients Not Receiving Avastin 15 glioma patients not receiving Avastin for recurrence studied in the same manner as Arm 1 DECT: DECT at tumor progression and 3 months later MR spectroscopy: MR spectroscopy at tumor progression and 3 months later
3 Month Response	3 participants who had tumor reduction	—

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Adverse event data not reported

Adverse event data not reported

London Health Sciences Hospital

Phone: 519-685-8650